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Equine arteritis virus (EAV) and porcine reproductive and respiratory syndrome virus (PRRSV) are
members of family Arteriviridae; they are highly species speciﬁc and differ signiﬁcantly in cellular tropism
in cultured cells. In this study we examined the role of the two major envelope proteins (GP5 and M)
of EAV and PRRSV in determining their cellular tropism. We generated three viable EAV/PRRSV chimeric
viruses by swapping the N-terminal ectodomains of these two proteins from PRRSV IA1107 strain into an
infectious cDNA clone of EAV (rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto). The
three chimeric viruses could only infect EAV susceptible cell lines but not PRRSV susceptible cells in culture.
Therefore, these data unequivocally demonstrate that the ectodomains of GP5 and M are not the major
determinants of cellular tropism, further supporting the recent ﬁndings that the minor envelope proteins are
the critical proteins in mediating cellular tropism (Tian et al., 2012).
& 2012 Elsevier Inc. All rights reserved.Introduction
Members of the family Arteriviridae include equine arteritis virus
(EAV), porcine reproductive and respiratory syndrome virus
(PRRSV), lactate dehydrogenase-elevating virus (LDV) of mice and
simian hemorrhagic fever virus (SHFV) (Cavanagh, 1997; Faaberg
et al., 2012). Arteriviruses are small, enveloped animal viruses with
an isometric core containing a positive sense RNA genome (Snijder
and Meulenberg, 1998, 2001). EAV and PRRSV are the causative
agents of equine viral arteritis (EVA) in horses and porcine repro-
ductive and respiratory syndrome (PRRS) in pigs, respectively (Dollll rights reserved.
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tes.et al., 1957; Russell et al., 1980; Wensvoort et al., 1991). The EAV
and PRRSV genomes are polycistronic and contain at least 10 open
reading frames [ORFs; (den Boon et al., 1991; Firth et al., 2011;
Johnson et al., 2011)]. The 50-proximal three-quarters are occupied
by two large ORFs (1a and 1b) that together encode all viral enzyme
functions (collectively referred to as ‘‘replicase’’) required for gen-
ome replication and subgenomic mRNA (sgmRNA) production (Fang
and Snijder, 2010; Snijder and Spaan, 2006). The ORFs 2a, 2b, 3, 4,
5a, 5, 6, and 7 of EAV and PRRSV are partially overlapping and are
located in the 3’-one-quarter of the genome, encoding seven
envelope proteins [E, GP2, GP3, GP4, ORF5a protein, GP5 and
membrane (M)] and a nucleocapsid protein (N) (Firth et al., 2011;
Johnson et al., 2011; Snijder and Meulenberg, 1998, 2001; Ziebuhr
et al., 2000). The glycosylated GP5 and the unglycosylated M protein
(encoded by ORF5 and ORF6, respectively) are the major envelope
proteins of EAV and PRRSV; they form a disulﬁde-linked hetero-
dimer in the mature virus particles (de Vries et al., 1995; Mardassi
et al., 1996). The formation of GP5/M heterodimer is critical for the
expression of neutralization epitopes of both viruses (Balasuriya
et al., 2002, 2000; Jiang et al., 2006; Ostrowski et al., 2002). The M
protein is the most conserved envelope protein of arteriviruses
(Faaberg, 2008). The GP5/M heterodimer is presumed to play
important roles in attachment to the host cell receptor and in cell
entry (Snijder and Meulenberg, 1998). In addition, the arterivirus
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proteins (GP2 [encoded by ORF2b in EAV and ORF2a in PRRSV], GP3
[encoded by ORF3] and GP4 [encoded by ORF4]) and two unglyco-
sylated envelope proteins (E [ORF2a in EAV and ORF2b in PRRSV]
(Wu et al., 2001, 2005) and ORF5a protein [ORF5a]) (Firth et al.,
2011; Johnson et al., 2011). It has also been shown by reverse
genetics that the elimination of ORF5a protein expression by knock-
ing out the start and stop codon will cripple EAV virus and lead to
progeny virus with a small plaque phenotype and a signiﬁcantly
reduced virus titer in transfected cells (Firth et al., 2011).
Arteriviruses are highly species speciﬁc and macrophages are
the primary target cells of virus replication (Balasuriya and
Snijder, 2008; Duan et al., 1997; Kim et al., 1993; Lawson et al.,
1997; Plagemann and Moennig, 1992; Rossow, 1998). However,
EAV can replicate in a variety of cells including equine pulmonary
artery endothelial (Hedges et al., 2001), horse kidney, rabbit
kidney and hamster kidney cells and a number of continuous cell
lines including baby hamster kidney (BHK-21) (Hyllseth, 1969;
Maess et al., 1970), rabbit kidney-13 (RK-13), African green
monkey kidney (VERO) (Konishi et al., 1975; Radwan and
Burger, 1973), rhesus monkey kidney (LLC-MK2), MARC-145 and
hamster lung (HmLu) (Konishi et al., 1975) cells. In contrast,
PRRSV can only replicate in a limited number of cell types. North
American PRRSV (Type 2) strains replicate in primary porcine
alveolar macrophages (PAM), and the African green monkey cell
line, MA-104, or its derivative, MARC-145 (Van Breedam et al.,
2010a). Most, if not all, European PRRSV (Type 1) strains replicate
best or exclusively in PAMs, but can be adapted to grow in
MA-104 derived cell lines, including CL2621 and MARC-145. UntilFig. 1. Schematic presentation of parental, recombinant and chimeric cDNA clones. O
introduced to separate ORF4 and 5 (AﬂII), and ORF 5 and 6 (NotI), and ORF 4, 5, and 6
regulate leader-body junction during viral subgenomic RNA synthesis are indicated by
(n). The N-terminal ectodomain or full-length of PRRSV GP5 protein is labeled in blue.recently, the viral envelope protein(s) involved in virus attach-
ment and entry of EAV and PRRSV have not been fully character-
ized (Das et al., 2011; Tian et al., 2012). In a previous study, Dobbe
et al. (2001) demonstrated that EAV expressing the ectodomain of
GP5 of PRRSV IAF-Klop strain (Pirzadeh et al., 1998) did not
change the cellular tropism of the virus. Recently, in our labora-
tory, we have developed an infectious cDNA clone of the modiﬁed
live virus (MLV) vaccine (ARVACs) of EAV (prMLVB) (Zhang et al.,
submitted for publication). This infectious cDNA clone was
originally developed to design a marker vaccine for EAV and to
increase the safety and efﬁcacy of the current MLV vaccine, as
well as a vector platform to express heterologous genes from
other viruses. In this study, we describe the use of this infectious
cDNA clone to characterize the role of the major envelope
proteins (GP5 and M) for investigating the cellular tropism of EAV.Results and discussion
Generation of EAV/PRRSV chimeric viruses
The infectious cDNA clone (prMLVB) of the MLV vaccine strain
of EAV (ARVACs) was used as the backbone to generate a panel of
5 recombinant chimeric viruses by replacing either the full-length
or the N-terminal ectodomains of GP5 and M proteins of EAV with
the IA-1107 strain of North American PRRSV (Fig. 1, Table 1).
Because of the overlapping gene arrangement in the 3’ end of the
EAV genome, it was necessary to separate ORF 5 from ﬂanking
ORFs 4 and 6 without disrupting the coding sequences of each ofnly the ORFs 4 to 7 and 30 nontranslated region is depicted. The restriction sites
(AﬂII and NotI) are depicted. The transcriptional regulatory sequences (TRS) that
triangles. The stop codon for each chimeric construct is identiﬁed with an asterisk
The N-terminal ectodomain or full-length of PRRSV M protein is labeled in green.
Table 1
Composition of the GP5 and M proteins of EAV–PRRSV chimeric constructs.
Construct Chimeric
protein
GP5 Fused to M Fused to Production of
progeny virusa
Plaque sizeb
(mm)
GenBank
number
prMLVB n.a.c Parental (pt) EAV GP5 n.a. pt EAV M n.a. þ 5 FJ798196
prMLVB4/5 n.a. pt EAV GP5 pt EAV M n.a. þ 2.4 JQ844153
prMLVB4/5
GP5ecto
GP5ecto PRRSV GP5 ectodomain
a.a. 1–64
EAV GP5 a.a.
115–255
pt EAV M n.a. þ 1 JQ844156
prMLVB4/5
GP5full
GP5full PRRSV GP5 full-length
a.a. 1–200
n.a. pt EAV M n.a.  n.a. n.a.
prMLVB5/6 n.a. pt EAV GP5 n.a. pt EAV M n.a. þ 3 JQ844154
prMLVB5/6 Mfull Mfull pt EAV GP5 n.a. PRRSV M full-length
a.a. 1–175
n.a.  n.a. n.a.
prMLVB4/5/6 n.a. pt EAV GP5 n.a. pt EAV M n.a. þ 2.8 JQ844155
prMLVB4/5/6
Mecto
Mecto pt EAV GP5 n.a. PRRSV M ectodomain
a.a. 1–17
EAV M a.a.
17–162
þ 0.5 JQ844157
prMLVB4/5/6
GP5&Mecto
GP5&Mecto PRRSV GP5 ectodomain
a.a. 1–64
EAV GP5 a.a.
115–255
PRRSV M ectodomain
a.a. 1–17
EAV M a.a.
17–162
þ 0.5 JQ844158
a The production of progeny virus was evaluated by IFA staining with EAV N antibody and development of cytopathic effect.
b Plaque morphology study was done in EEC.
c Not applicable.
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Fig. 2. Replication characteristics of parental rMLVB, recombinant rMLVB4/5,
rMLVB5/6 and rMLVB4/5/6 and chimeric rMLVB4/5 GP5ecto, rMLBV4/5/6 Mecto
and rMLVB4/5/6 GP5&Mecto viruses in BHK-21 cells. Subconﬂuent monolayers of
BHK-21 cells were grown in 6-well plates, inoculated with each P0 virus (MOI of 1)
and incubated at 37 1C for 1 h. After removal of the inoculum, the cells were rinsed
three times with PBS and overlaid with 4 ml of EMEM. At indicated time points,
supernatants were harvested and titrated by plaque assay in RK-13 cells.
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6 were separated in the prMLVB plasmid to generate the plasmids
prMLVB4/5, prMLVB5/6 and prMLVB4/5/6 (GenBank accession
numbers JQ844153, JQ844154 and JQ844155), respectively. The
authenticities of these plasmid constructs were ﬁrst conﬁrmed by
sequencing ORFs 4–7 (data not shown). The same amount of full-
length in vitro transcribed (IVT) RNA generated from linearized
prMLVB, as well as mutant prMLVB4/5, prMLVB5/6 and prMLVB4/
5/6 cDNA clones were electroporated into BHK-21 cells for gen-
eration of recombinant viruses as previously described (Balasuriya
et al., 1999; van Dinten et al., 1997). The viability of each
recombinant clone was determined by indirect immunoﬂuores-
cence assay (IFA) using EAV N protein speciﬁc monoclonal anti-
body (MAb 3E2) to stain BHK-21 cells 24 h post transfection with
IVT RNA generated from each linearized plasmid construct (data
not shown). The cells transfected with each of the three recombi-
nant transcripts produced 90–100% cytopathic effect (CPE) in
transfected cells after 72–96 h post transfection, and virus stocks
were made from these tissue culture ﬂuids (TCF; P0). The authen-
ticity of all three recombinant viruses was conﬁrmed by sequen-
cing ORFs 4–7 from RNA extracted from each TCF (P0). All virus
sequences were identical to the plasmid sequence from which
they were derived. The TCFs (P0) containing each recombinant
virus were then used to infect BHK-21 cells at a multiplicity of
infection (MOI) of 1 and progeny viruses were collected at
different time points for titration. The growth characteristics and
plaque morphology were compared in RK-13 and EEC, respec-
tively. All of the recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/
6 viruses had the highest progeny virus titer at 48 h post infection.
They had approximately 2 log10 lower titer as compared to the
parental rMLVB virus at this time point (Fig. 2). When compared to
the parental virus, the recombinant viruses showed a 48–60%
reduction in plaque size in EECs. The parental rMLVB produced
5 mm diameter large sized plaques while the recombinant
rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 produced 2.4, 3 and
2.8 mm diameter medium sized plaques in EECs, respectively.
However, there was no signiﬁcant difference in growth character-
istics among these three recombinant viruses. All three recombi-
nant viruses were stable for more than 10 serial passages in BHK-
21 cells. The separation of these ORFs did not alter the amino acid
sequence of GP4, GP5 and M proteins of EAV but the ORFs 4/5
separation changed the N-terminal amino acid sequence of ORF5a
protein (Fig. 3). In a recent study, we demonstrated that completeelimination of ORF5a protein experimentally could lead to 2–3 log
lower virus titer and tiny plaques (Firth et al., 2011). Interestingly,
the addition of extra nucleotides to the ORF5a coding sequence did
not cripple the recombinant viruses to the same extent as the
ORF5a knockout virus (Firth et al., 2011) indicating that this region
of the EAV genome could accept insertion of a small stretch of
nucleotides (see below). Collectively, these data demonstrated
that separation of these ORFs have somewhat compromised the
derived viruses but the recombinant constructs were stable and
could be used for further studies. The next step was to generate a
panel of EAV–PRRSV chimeric plasmids by replacing the nucleo-
tide (nt) sequence encoding the N-terminal ectodomain or full-
length of GP5 and/or the M protein on an EAV backbone with
corresponding sequences from North American PRRSV IA1107
strain using prMLVB4/5, prMLVB5/6 and prMLVB4/5/6 plasmids
(Fig. 1, Table 1). We have exchanged the N-terminal ectodomain
Fig. 3. Sequence alignments of amino acids of the ORF5a and GP5 proteins of parental EAV and chimeric viruses. The amino acid sequence changes due to ORF4 and
5 separations are highlighted in blue. The remaining ORF5 from EAVrMLVB backbone in the GP5ecto chimera construct is marked in green. The ectodomains of PRRSV are
labeled in red. The common region of ORF5a between PRRSV and GP5ecto chimera is labeled in purple. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
Z. Lu et al. / Virology 432 (2012) 99–109102(a.a. 1–64) and full-length (a.a. 1–200) of PRRSV GP5 with
ectodomain (a.a. 1–114) of EAV GP5 to generate prMLVB4/5
GP5ecto and prMLVB4/5 GP5full constructs on a prMLVB4/5
backbone. Similarly, the N-terminal ectodomain (a.a. 1–17) and
full-length (a.a. 1–175) of PRRSV M were exchanged with the
N-terminal ectodomain (a.a. 1–16) of EAV M protein, respectively,
to generate prMLVB4/5/6 Mecto and prMLVB5/6 Mfull constructs
on the prMLVB4/5/6 and prMLVB5/6 backbones, respectively
(Fig. 1, Table 1). The ORF5 and ORF6 regions of all chimeric
plasmid constructs were RT-PCR ampliﬁed with two EAV speciﬁc
primers (10763P and 12568N) and visualized by agarose gel
electrophoresis (data not shown). Subsequently, the RT-PCR pro-
ducts were sequenced to conﬁrm the authenticity of the chimeric
plasmid constructs. All chimeric constructs maintained in-frame
coding sequences in ORF5a, ORF5 and ORF6. Full-length IVT RNAs
from linearized chimeric plasmids were transfected into BHK-21
cells as previously described (Balasuriya et al., 1999; van Dinten
et al., 1997). A portion of transfected cells were seeded into
chamber slides for IFA staining to check for the expression of
EAV N protein 24 h post transfection. With the exception of BHK-
21 transfected with prMLVB4/5 GP5full and prMLVB5/6 Mfull,
cells transfected with prMLVB4/5 GP5ecto, prMLVB4/5/6 Mecto
and prMVLB4/5/6 GP5&Mecto stained positive for EAV N protein
(data not shown). This observation was further conﬁrmed by the
development of 90–100% CPE 72–120 h post transfection in BHK-
21 cells that were transfected with IVT RNA from prMLVB4/5
GP5ecto, prMLVB4/5/6 Mecto and prMLVB4/5/6 GP5&Mecto. The
experiments have been repeated twice on separate occasions.
Collectively, these data suggested that only 3 of the 5 chimeric
constructs could produce infectious progeny viruses. Each of the
three progeny viruses was harvested (P0) and subjected to further
in vitro characterization. Of the 5 chimeric constructs, only rMLVB4/5
GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto couldgenerate infectious progeny viruses following transfection of IVT
RNA into BHK-21 cells (GenBank accession numbers JQ844156,
JQ844157 and JQ844158, respectively). The IVT RNA generated from
plasmids containing full-length GP5 or M replacement of PRRSV IA-
1107 strain (prMLVB4/5 GP5full and prMLVB5/6 Mfull) failed to
generate infectious progeny viruses. The genetic stabilities of each of
the three replicating chimeric viruses were determined by 10 serial
passages in BHK-21 cells and subsequent RT-PCR ampliﬁcation and
sequencing of ORF5–6 from RNA extracted from P0, P5 and P10 TCF.
The sequence data revealed no substitutions, insertions or deletions
in this region of all three chimeric viruses following serial cell culture
passage. These results unequivocally demonstrated that these three
chimeric viruses are highly stable following serial passage in cell
culture. The failure to generate chimeric viruses containing full-
length PRRSV GP5 or M protein on the EAV backbone may be due to
the fact that being the smallest arterivirus in the family Arteriviridae,
EAV has evolved to the point that it is unable to accept any large
nucleotide inserts into the genome. However, it has been reported
that EAV can tolerate small segments of nucleotides in the structural
proteins genes (de Vries et al., 2001; Dobbe et al., 2001). It is also
possible that the conformational interaction between GP5 and M
proteins requires both the homologous transmembrane and cyto-
plasmic tails of these two proteins for proper protein folding and
expression. We cannot exclude other possibilities such as the
cytoplasmic domains of the GP5 and M proteins are required for
speciﬁc interaction with other viral proteins such as nucleocaspid
protein for the assembly of infectious virions.
Growth characteristic and plaque morphology of EAV/PRRSV chimeric
viruses
The growth characteristics and plaque morphologies of rMLVB4/
5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto
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tively, as described before. All three EAV–PRRSV chimeric viruses
rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6
GP5&Mecto had similar growth curves. Replication titers were
3 log10 lower as compared to parental rMLVB virus and 1 log lower
as compared to the recombinant cloned viruses (rMLVB 4/5 and
rMLVB4/5/6); these were derived 48 h post infection (Fig. 2).
Furthermore, P5 and P10 TCF of all three chimeric viruses had
similar growth curves as compared to P0 TCF (Table 2). Plaque
assays were performed in EECs for all three chimeric viruses and
their plaque morphology was compared to parental rMLVB,
recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 viruses. The
three chimeric viruses (rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto
and rMLVB4/5/6 GP5&Mecto) produced small sized plaques
(0.5 mm to 1 mm) as compared to the parental rMLVB virus
(5 mm) and the three recombinant viruses from which the
chimeric viruses were derived from 2.4–3 mm). The lower titers
and smaller plaque sizes of the chimeric viruses clearly indicated
that although the viruses are genetically stable (Fig. 4), they have
signiﬁcantly compromised phenotypes as reﬂected in limited
replication and spreading when compared to the parental rMLVB
or the three recombinant viruses from which they were derived
(ORF4/5, ORF5/6 and ORFs4/5/6). Interestingly, when progeny
viruses (P0) produced in BHK-21 cells were titrated in RK-13 cells
for growth curve analysis, the reduction in titer of the chimeric
viruses was not as signiﬁcant as that observed in EECs, in which
there was a reduction in plaque size (medium to pinpoint).
This observation suggested that infection and spreading was
inﬂuenced by the cell type in which the viruses are propagated.
Speciﬁcally, EAV ﬁeld strains produced different plaque sizes in
EEC but not in RK-13 (Moore et al., 2003). Taken together, the data
clearly showed that the presence of PRRSV N-terminal ectodo-
mains of GP5 and M altered the growth characteristics and cell to
cell spread of the chimeric viruses. Furthermore, it has long been
proposed that the GP5 and M proteins of arteriviruses play a major
role in virus attachment (Balasuriya et al., 1997; Van Breedam
et al., 2010b). Similarly, nonspeciﬁc interactions have been shown
between PRRSV M protein and a heparin-like receptor on PAM
cells (Delputte et al., 2002).Cellular tropism of EAV/PRRSV chimeric viruses
Although EAV and PRRSV infect cells from the monocyte/
macrophage lineage in their natural host, they present different
cellular tropisms in cell culture (Duan et al., 1997; Plagemann andTable 2
Stability of EAV–PRRSV chimeric viruses following 10 serial passages in BHK-21
cells.
Virus
passage
Virus titer (pfu/ml)
rMLVB4/5
GP5ecto
rMLVB4/5/6
Mecto
rMLVB4/5/6
GP5&Mecto
P0a 3.5106 8.2105 2.6106
P1 1.1106 3.8105 3.6106
P2 1.2106 3.4105 1.5106
P3 1.3106 5.1105 2.1106
P4 8.3105 2.6105 2.4106
P5a 1.0106 2.5105 2.5106
P6 5.5106 8.9105 3.0106
P7 1.3106 1.6105 1.3106
P8 5.9106 2.6105 5.4106
P9 2.0106 1.8105 1.7106
P10a 9.7106 7.3105 2.3106
a P0, P5 and P10 viruses were sequenced and found genetically stable.Moennig, 1992; Snijder and Meulenberg, 1998). EAV can infect a
wide variety of cell lines while PRRSV can only infect PAM and
African green monkey kidney (MA-104) cells and the derivative
(MARC-145) cell line (Kim et al., 1993; Snijder and Meulenberg,
1998). The chimeric viruses derived by swapping the ectodomains
of PRRSV GP5 and M proteins into an EAV backbone provide
valuable tools to study cellular tropisms. The three viable
chimeric viruses were tested in different EAV-susceptible cell
lines (EEC, RK-13, BHK-21, MARC-145), PRRSV-susceptible cells
(PAM and MARC-145) and porcine alveolar macrophage cell line
(3D4/21) to conﬁrm cellular tropism and infectivity of the
progeny virus. Virus replication in various cell lines was deter-
mined by IFA staining with MAb 3E2 (a-N of EAV) and polyclonal
pig anti-PRRSV serum (Fig. 5 and Table 3). Interestingly, the three
chimeric viruses (rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and
rMLVB4/5/6 GP5&Mecto), along with the rMLVB parental virus,
were able to infect EEC, MARC-145, BHK-21, and RK-13 cells but
not PAM and 3D4/21 cells as determined by IFA staining for the N
protein of EAV (Fig. 5). PRRSV was able to infect PAM and MARC-
145 cells but not EEC, BHK-21, RK-13 and 3D4/21 cells based on
presence or absence of staining with PRRSV-speciﬁc monoclonal
antibody against the nucleocapsid protein (Fig. 5). Furthermore,
MARC-145 cells were infected with the wild type PRRSV, parental
rMLVB and the three chimeric viruses (rMLVB4/5 GP5ecto,
rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto) on IFA staining
with pig anti-PRRSV polyclonal serum. Positive staining was
observed in MARC-145 cells infected with PRRSV and three
chimeric viruses indicating that PRRSV GP5 and/or M proteins
are expressed in the three chimeric viruses (Fig. 5B). None of the
viruses were able to infect 3D4/21 cells. This ﬁnding was
consistent with previous observations that 3D4/21, a continuous
porcine alveolar macrophage cell line, does not support replica-
tion of PRRSV (Weingartl et al., 2002). The exchange of GP5 and/or
M protein N-terminal ectodomains from PRRSV (individual or
double) could not alter the tropism of the chimeric viruses.
Similarly, a previous study has shown that exchanging the GP5
ectodomains from another PRRSV IAF-Klop strain did not change
the cell tropism of EAV or PRRSV (Dobbe et al., 2001). In that
study, it was shown that chimeric viruses containing the N-term-
inal ectodomains of M envelope proteins of PRRSV and LDV on an
EAV backbone are replication- and transcription-competent (as
determined by the synthesis of both non-structural and structural
proteins), but unable to produce infectious progeny virus. Dobbe
et al. (2001) indicated that this was due to the failure of formation
of the GP5/M heterodimer in the chimeric proteins. In contrast,
we demonstrated that the N-terminal ectodomain of the M
protein of EAV can be replaced by the N-terminal ectodomain of
PRRSV M protein without compromising the production of viable
progeny virus using a different infectious cDNA clone of EAV and
a more recent North American strain of PRRSV IA1107. Our
ﬁndings indicate that neither the GP5 nor M protein is involved
in determining the cellular tropism of EAV. This supports the
hypothesis that EAV and perhaps PRRSV major envelope proteins
are not determinants of the cellular tropism of these two viruses.
Interestingly, in a very recent study, a PRRSV infectious cDNA
clone was used as a vector to construct a chimera in which PRRSV
ORFs 2a, 2b, 3 and 4 were replaced by the corresponding ORFs
from EAV (Tian et al., 2012). This PRRSV/EAV chimeric virus
acquired the broad cell tropism that is typical of EAV, which
clearly indicated that the minor envelope protein (GP2, GP3 and
GP4) and E protein play a key role in determining the cellular
tropism of arteriviruses and these play a major role in virus
attachment and entry (Tian et al., 2012). However, the major
neutralization determinants of EAV and PRRSV are both localized
in the N-terminal ectodomain of GP5 (Balasuriya et al., 1995,
1997; Ostrowski et al., 2002; Plagemann, 2004; Plagemann et al.,
rMLVB4/5/6 Mecto
rMLVB4/5 rMLVB4/5/6
Parental rMLVB
rMLVB4/5 GP5ecto rMLVB4/5/6 GP5&Mecto
rMLVB5/6
Mutant 
EAV515-Δ5a
Mutant 
VBS-Δ5a
rMLVB4/5Parental rMLVB rMLVB4/5 GP5ecto
Fig. 4. (A) Comparison of plaque morphology on equine endothelial cells (EEC) of parental rMLVB, recombinant rMLVB4/5, rMLVB5/6 and rMLVB4/5/6 and chimeric
rMLVB4/5 GP5ecto, rMLVB4/5/6 Mecto and rMLVB4/5/6 GP5&Mecto viruses. (B) Illustration of plaque morphology of ORF5a knockout mutants (EAV515-D5a, VBS-D5a) as
compared to the parental rMLVB, recombinant rMLVB4/5 and chimeric rMLVB4/5/ GP5ecto viruses. The insertion of 8–10 amino acids into the ORF5a protein of EAV did
not cripple the virus to the same extent as the knockout mutants. The mutant EAV515-D5a and the mutant VBS-D5a plaque morphology ﬁgures were reproduced from
Firth et al., (2011) with permission.
Z. Lu et al. / Virology 432 (2012) 99–1091042002). As we have shown previously, recombinant EAV (A45.C2)
containing the GP5 ectodomain of PRRSV (IAF-Klop) is not
neutralized by any EAV speciﬁc MAbs or by the polyclonal equine
antisera (Balasuriya et al., 2004). Therefore, it will be interesting
to determine the replication and immunogenic kinetics of these
viable EAV/PRRSV chimeras in pigs.
Effect of ORFs4/5 and ORFs5/6 separations on ORF5a protein and GP5
proteins
Recently, a novel small ORF5a protein (encoded by ORF5a)
which overlaps with the 50 end of ORF5 has been identiﬁed in
both EAV and PRRSV (Firth et al., 2011; Johnson et al., 2011). The
effect of ORF4/5 separation on ORF5a protein and GP5 was
determined by comparative amino acid sequence analysis
(Fig. 3). Insertion of the 24 nucleotide sequence to separate
ORFs4/5 in the prMLVB vector resulted in replacement of 4 amino
acids (NAIY [a.a. 12–15]) with 12 amino acids (SAICELKOHAVH
[a.a. 12–23]); this expanded the length of the EAV ORF5a protein
by 8 amino acids. The insertion of 24 nucleotides did not affect
the transcriptional regulatory sequence (TRS) upstream of ORF5of rMLVB4/5. It also did not alter the coding sequences of GP5 and
M proteins nor the TRS upstream of ORF6. The growth curve and
plaque morphology of rMLVB4/5 indicated that separation of
ORF4/5/6 had some negative impact on the recombinant viruses.
However, these changes did not have a signiﬁcant crippling effect
on the recombinant virus. Previously it was reported that a
complete knock out of the ORF5a protein in two infectious cDNA
clones pEAV515, a derivative of pEAV030 (van Dinten et al., 1997)
and pEAVrVBS (Balasuriya et al., 2007), had a signiﬁcant crippling
effect on the progeny viruses, which produced lower titered virus
and pinpoint plaques (Firth et al., 2011). In the current study,
insertion of 8 random amino acids to the ORF5a protein of EAV
ORF4/5 recombinant virus did not cripple the virus to the same
extent compared to the ORF5a knockout mutants (Fig. 4B).
Following the replacement of EAV GP5 N-terminal ectodomain
(a.a. 1–114) with PRRSV IA1107 GP5 N-terminal ectodomain (a.a
1–64), the new EAV/PRRSV fusion ORF5a protein consists of 11
amino acids (MFFYDWYVGLN) from EAV ORF5a protein followed
by 10 random amino acids (SAICELKQHV) encoded by the nucleo-
tide sequence that was inserted for the separation of ORFs4/5 and
the PRRSV ORF5a amino acid sequence (a.a. 22–62) corresponding
PAM
α-sera (PRRSV)
3D4/21
rMLVB        GP5ecto          Mecto            GP5&MectoPRRSV
Viruses
BHK-21
RK-13 
EEC
α-N (EAV, 3E2 )α-N (PRRSV, SDOW17)
MARC-145
MARC-145
Fig. 5. Determination of cellular tropism of EAV–PRRSV chimeric viruses using indirect immunoﬂuorescence assay (IFA). Various cell lines used in this study are listed on
the left side of the ﬁgure. The names of the P0 viruses used to infect cells are identiﬁed at the top center. The primary antibodies or anti-sera used in IFA are shown at the
bottom of the ﬁgure. In (A) PRRSV infected cells (ﬁrst column) were stained with FITC-conjugated SDOW17 MAb which was used to stain PRRSV N protein (green). The
remaining columns show the chimeric virus-infected cell lines stained with EAV MAb (3E2) against N protein followed by Texas-red conjugated secondary antibody
staining (red). In (B), MARC-145 cells infected with PRRSV or rMLVB or chimeric viruses were stained with pig polyclonal anti-PRRSV sera followed by FITC-conjugated
secondary antibody staining. Cell nucleus was stained by Hoechst 33342 (blue). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
Table 3
Cellular tropism of various chimeric viruses to different cell types as compared to PRRSV and EAV.
PRRSV EAV rMLVB rMLVB4/5 GP5ecto rMLVB4/5 GP5full rMLVB4/5/6 Mecto rMLVB5/6 Mfull rMLVB4/5/6 GP5&Mecto
PAMa þ      
3D4/21       
Marc 145 þ þ þ  þ  þ
EEC  þ þ  þ  þ
BHK-21  þ þ  þ  þ
RK-13 HP  þ þ  þ  þ
Notes Non-infectious Non-infectious
a Porcine alveolar macrophage.
Z. Lu et al. / Virology 432 (2012) 99–109 105to amino acids 6 to 46 of the PRRSV ORF5a protein. The
recombinant EAV/PRRSV ORF5a fusion protein containing the
PRRSV GP5 ectodomain was 16 amino acids longer (46 versus
62 a.a.) than the authentic protein and its ﬁrst 11 amino acids
were identical to those in the EAV ORF5a protein. Interestingly,
the chimeric viruses with this ORF5a protein (rMLVB4/5 GP5ecto
and rMLVB GP5&Mecto) were stable and replicated to titers of9.5105 pfu/ml. Taken together, these data further conﬁrmed the
importance of the ORF5a protein in virus infection as well as the
plasticity of this region in having able to accommodate small
stretches of additional nucleotides. This observation is further
supported by previous attempts to engineer an EAV vectored
vaccine by fortuitously introducing a 24 nt insertion to disrupt
the ORF4/5 overlap (de Vries et al., 2000). Furthermore, the
Z. Lu et al. / Virology 432 (2012) 99–109106difference in length of the ORF5a protein among arteriviruses
(EAV 59 codons, PRRSV-NA 46 or 56 codons, PRRSV-EU 43 codons,
LDV 47 codons and SHFV 64 codons) and spontaneous insertion of
12 nt into ORF5a during 70 serial passages of PRRSV-NA strain
(Han et al., 2009) conﬁrm the plasticity of this region of EAV and
other arteriviruses.
In summary, in this study, we have generated three viable
EAV/PRRSV chimeric viruses (rMLVB4/5 GP5ecto, rMLVB4/5/6
Mecto and rMLVB4/5/6 GP5&Mecto). The chimeric viruses con-
taining PRRSV M ectodomain are novel. We have used these three
viruses to demonstrate unequivocally that the ectodomains of
GP5 and M are not the major determinants of cellular tropism,
further supporting the recent ﬁndings that the minor envelope
proteins GP2, GP3, GP4 and E are the critical proteins in mediating
cellular tropism (Tian et al., 2012).Material and methods
Cells and viruses
The cell lines used in the study included equine pulmonary
artery endothelial cells (EECs, P12 to P22) (Hedges et al., 2001), high
passage rabbit kidney-13 cells (RK-13 KY, P399 to P409), baby
hamster kidney cells (BHK-21 [ATCC CRL-12072], Manassas, VA),
MARC-145 cells and porcine macrophage cells 3D4/21 (ATCC CRL-
2843, Manassas, VA). The EECs were maintained in DMEMwith high
glucose supplemented with 10% fetal bovine serum (Hyclone, Logan,
UT), penicillin, streptomycin, L-glutamine and non-essential amino
acids (Life Technologies, Grand Island, NY). RK-13 KY, BHK-21 and
MARC-145 were maintained at 37 1C in Eagle’s minimum essential
medium with 10% ferritin-supplemented bovine calf serum
(Hyclone, Logan, UT) penicillin, streptomycin, amphotericin B, and
sodium bicarbonate (Life Technologies, Grand Island, NY). In addi-
tion, porcine alveolar macrophages (PAM) were isolated and stored
at 80 1C until used (kindly provided by Dr. Kay Faaberg, USDA-
ARS, Ames, IA). The PAM cells were maintained in Dulbecco’s MEM
supplemented with 5% fetal bovine serum and 5% antibiotic/anti-
mycotic (Life Technologies, Grand Island, NY). The PRRSV IA1107
strain was kindly provided by Fort Dodge Animal Health Labora-
tories (now Pﬁzer Animal Health Inc., Kalamazoo, MI). This strain
was isolated from the lung of a pig that died of PRRS. Working virus
stock of this strain was made by passaging once in MARC-145 cells.
Construction of EAV/PRRSV chimeric infectious cDNA clones by
swapping ORF5 and 6 from PRRSV
The development and characterization of an infectious cDNA
clone (prMLVB) of the modiﬁed live vaccine strain of EAV
(ARVACs) that was used as the backbone to develop the chimeric
viruses has been previously described (Zhang et al., submitted for
publication) (GenBank accession number FJ798196). The genera-
tion of chimeric infectious cDNA clones was performed by a
previously described method with some modiﬁcations (de Vries
et al., 2000). Brieﬂy, three plasmid constructs were generated by
separating the overlapping regions between ORFs 4/5 and 5/6 of
the prMLVB infectious cDNA clone of EAV (Fig. 1). The unique
XbaI site at nt position 14530–14535 was knocked out in the
prMLVB clone to generate the shuttle vector prMLVB-XbaIko to
facilitate the cloning strategy. The ORFs 4/5 overlapping region
(11144CAATGCTATCTATGATT11160) was ﬁrst removed from the
prMLVB-XbaIko clone by site-directed mutagenesis and then the
50CAGTGCTATCTGTGAacttaagcaacatgctgtccatgaTT30 sequence was
inserted into the corresponding region to obtain the prMLVB4/5
(GenBank accession number JQ844153) in which the ORF4 and
ORF5 overlapping regions were separated. A unique restrictionsite AfIII (50CTTAAG30) was introduced into the region separating
ORF4 and ORF5. Similarly, the ORFs 5/6 overlapping region
11899GTATGGGAGCCATAGAT11915 was removed from the prMLVB-
XbaIko clone by insertion of the nucleotides 50GTGTGGGAG
CCATAGagcggccgccaatgggagccatagAT30 into the corresponding
region to obtain the clone prMLVB5/6 (GenBank accession num-
ber JQ844154). A unique restriction site NotI (50GCGGCCGC30)
was introduced into the region separating ORF5 and ORF6 to
facilitate the next cloning step. Subsequently, using a similar
approach, a third construct was developed in which both 4/5 and
5/6 ORFs were separated (prMLVB4/5/6, GenBank accession number
JQ844155). These three clones were used to generate various EAV/
PRRSV chimeric viruses by swapping ORF5 and ORF6 (N-terminal
ectodomains and as well as full-length) from PRRSV IA1107 strain.
The GP5 N-terminal ectodomain of PRRSV IA1107 strain (nt
11788–11979; numbered according to GenBank accession num-
ber U87392) was reverse transcribed with primer PVGP5ectoN
followed by PCR ampliﬁcation using primers PVGP5ectoP and
PVGP5ectoN (Supplementary Table 1) using a commercial
one-step RT-PCR kit (Qiagen, Valencia, CA). The PRRSV GP5
ectodomain was then cloned into the plasmid prMLVB4/5 using
unique restriction sites AﬂII and EcoRI to obtain the recombinant
plasmid prMLVB4/5 GP5ecto (GenBank accession number
JQ844156). The GP5 full-length domain of PRRSV IA1107 (nt
13788–14390) was RT-PCR ampliﬁed with primer PV15364N
followed by PCR ampliﬁcation using primers PVGP5ectoP and
PVGP5fullN and cloned into prMLVB4/5 with restriction sites NotI
and XbaI to obtain the recombinant plasmid prMLVB4/5 GP5full.
Similarly, the M full-length domain of PRRSV IA1107 (nt 14375–
14899) was reverse transcribed with primer PV15364N and PCR
ampliﬁed using primers PVMfullP and PVMfullN and cloned into
prMLVB5/6 with restriction sites NotI and XbaI to generate the
chimera construct prMLVB5/6 Mfull. Because of the short length
of the M protein N-terminal ectodomain sequence, the N-terminal
ectodomain of PRRSV IA1107 M protein (nt 14375–14425) was
directly inserted into the shuttle vector prMLVB-XbaIko4/5/
6RemMecto, in which the M protein N-terminal ectodomain of
EAV was removed via site-directed mutagenesis, using primer
EAVinsPVMectoP and EAVinsIA1107MectoN to generate
prMLVB4/5/6 Mecto (GenBank accession number JQ844157).
The speciﬁc nucleotide locations were identiﬁed according to the
North American VR2332 strain of PRRSV sequence (GenBank
accession number U87392). The prMLVB4/5/6 Mecto was further
used as a vector to introduce the PRRSV GP5 N-terminal ectodo-
main sequences using the above described cloning strategies to
generate prMLVB4/5/6 GP5&Mecto plasmid (GenBank accession
number JQ844158). The nucleotide sequences of the primers used
in this study are listed in Supplementary Table 1. The panel of
chimeric constructs between the EAV and PRRSV major envelope
protein coding genes is shown in Fig. 1.
Sequencing of the plasmid constructs
The region spanning from ORFs 4–7 of prMLVB4/5, prMLVB5/6,
and prMLVB4/5/6 plasmids, as well as all ﬁve chimeric plasmids
were PCR ampliﬁed and sequenced to conﬁrm their authenticity.
Brieﬂy, each of the plasmids was ampliﬁed using primers that
were speciﬁc for the 50 end of the ORFs 4 and the 30 end of ORF7
(10763P and 12568N primers [Supplementary Table 1]; num-
bered according to the published sequence of the VB strain of
EAV, GenBank accession number DQ846750) using the high-
ﬁdelity proofreading Pfu Turbo DNA polymerase (Agilent Tech-
nology, Santa Clara, CA) according to a previously described
protocol (Zhang et al., 2008). Both sense and antisense strands
of the chimeric plasmids were sequenced using EAV speciﬁc
primers 10763P, 11691N, 11557P and 12568N (Supplementary
Z. Lu et al. / Virology 432 (2012) 99–109 107Table 1) at MWG Operon, Huntsville, AL. The sequence data were
analyzed using Aligner version 1.5.2 (CodonCode, Dedham, MA)
software program. Comparative nucleotide and amino acid
sequence analysis of the 30-end of all the plasmid were performed
with Vector NTI (Life Technologies, Carlsbad, CA) software.
In vitro transcription (IVT) and generation of recombinant chimeric
viruses
Run-off viral RNA transcripts from each recombinant/chimeric
infectious clone after linearization with restriction enzyme XhoI
were generated as previously described (van Dinten et al., 1997).
Eighty micrograms of full-length IVT RNA generated from each
recombinant and chimeric plasmid construct were transfected
into BHK-21 cells by electroporation as previously described
(Balasuriya et al., 1999; van Dinten et al., 1997). After electro-
poration, cells were incubated at room temperature for 10 min
and mixed with 12 ml of complete BHK-21 medium warmed to
room temperature. The cells were seeded into 10-cm-diameter
tissue culture plates (Falcon) and incubated at 37 1C for 48–72 h
until cytopathic effect (CPE) was evident. The tissue culture ﬂuid
(TCF) supernatant collected after IVT RNA transfection was
designated P0 virus and used for further characterization. The
stability of each recombinant/chimeric virus was determined by
10 sequential passages in BHK-21 cells and sequencing the RNA
extracted from passages 0, 5 and 10 (see below).
RT-PCR ampliﬁcation and sequencing of ORFs 5–6 of recombinant
viruses
The authenticity of each recombinant/chimeric virus stock was
determined by RT-PCR ampliﬁcation and sequencing of the ORFs
5–6 region from RNA that was isolated from TCF from P0, P5 and
P10 of each virus as previously described (Balasuriya et al., 1999).
Brieﬂy, RNA was directly isolated from the TCF using QIAmp viral
RNA isolation kit (Qiagen, Valencia, CA). The puriﬁed RNA was
treated with DNase I (Life Technologies, Grand Island, NY) for
30 min at 37 1C to remove any contaminating plasmid DNA before
RT-PCR ampliﬁcation. The ORFs 5–6 region was RT-PCR ampliﬁed
using EAV speciﬁc primers 10763P and 12568N (Supplementary
Table 1). The PCR was also performed with a non-RT step to
eliminate the possibility of amplifying any remaining plasmid
DNA. Sequence data were analyzed as described previously.
Antibodies
The monoclonal antibodies (MAbs) 3E2 and SDOW-17 (Rural
Technology Inc., Brookings, SD) against N proteins of EAV and
PRRSV, respectively, have been previously described (MacLachlan
et al., 1998; Nelson et al., 1993). Swine polyclonal anti-PRRSV
serum (PHGB 2008 ID#1467) was obtained from a PRRSV infected
pig with high PRRSV neutralizing activity. Commercial ﬂuorescent
labeled anti-swine (FITC conjugated anti-swine IgG [Santa Cruz
Biotechnology, Santa Cruz, CA]) and anti-mouse (Texas red-con-
jugated goat anti-mouse IgG [Thermo Scientiﬁc, Rockford, IL])
were used in indirect immunoﬂuorescence assays.
Indirect immunoﬂuorescence assay (IFA)
Various cell types (EEC, BHK-21, RK-13, PAM, 3D4/21, MARC-
145) grown in Lab-TekTM eight-well chamber slides (Nalge-Nunc,
Rochester, NY) were either mock infected or infected with various
recombinant chimeric viruses (P0) and incubated at 37 1C for 36–
48 h. The slides were ﬁxed with 3% paraformaldehyde in PBS
(pH¼7.4) and stained with EAV N protein speciﬁc MAb 3E2
followed by secondary Texas red-conjugated goat anti-mouseIgG staining. The BHK-21, RK13, EECs, MARC-145, PAM and
3D4/21 cells infected with PRRSV were stained with FITC con-
jugated MAb against PRRSV N protein (SDOW-17) (MacLachlan
et al., 1998; Nelson et al., 1993). Since PRRSV GP5 and M protein
speciﬁc antibodies were not available, swine polyclonal anti-
PRRSV serum was used to detect the chimeric PRRSV proteins in
infected cells. EAV antibodies were incubated for 1 h at room
temperature prior to secondary antibody staining. PRRSV MAb
against N protein (SDOW-17) or swine polyclonal anti-PRRSV
serum was incubated for 1 h at 37 1C followed by overnight
incubation at 4 1C to enhance the antibody signal.
In vitro growth characteristics of EAV–PRRSV chimeric viruses
BHK-21 cells grown in six-well plates were inoculated with
EAV–PRRSV chimeric viruses (P0) as well as parental rMLVB virus
and its derivatives (rMLVB4/5, rMLVB5/6 and rMLVB4/5/6) at an
MOI of 1 and incubated at 37 1C for 1 h. The inocula were
removed and cells were washed with PBS (pH¼7.4) three times
to remove unbound virus before being overlaid with 4 ml of
EMEM. At 0, 6, 12, 24, 48, 72 h post-infection, TCFs were collected
and virus titers were determined by plaque assays in RK-13 cells
as previously described (Wilson et al., 1962).
Plaque morphology
The plaque morphology of the recombinant viruses was
determined by plaque assays in EECs. Brieﬂy, conﬂuent mono-
layers of EECs in 6-well culture plates were infected with serial
10-fold dilutions of each recombinant/chimeric virus (rMLVB,
rMLVB4/5 and rMLVB4/5/6, rMLVB4/5 GP5ecto, rMLVB4/5/6
Mecto and rMLVB4/5/6 GP5&Mecto) virus in duplicate. Following
1 h incubation, 0.75% CMC (caboxymethylcellulose)–DMEM was
added to each well and cells were incubated at 37 1C for 96 h
(McCollum et al., 1961). Plaques were stained with 1% formalin–
crystal violet solution containing 1% formaldehyde at 96 h post-
infection and titers were expressed in pfu/ml.Acknowledgments
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